{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:12:47Z","timestamp":1784106767949,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0776-8","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T20:32:23Z","timestamp":1519331543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wajnrajch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"776_CR1","unstructured":"Zimran A, Elstein D. Gaucher disease and related lysosomal storage diseases. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press O, Burns L, et al., editors. Williams Hematology. 9th ed. New York: McGraw-Hill Education; 2016. p. 1121\u201333."},{"issue":"Suppl 1","key":"776_CR2","first-page":"82","volume":"12","author":"A Zimran","year":"2014","unstructured":"Zimran A, Elstein D. Management of Gaucher disease: enzyme replacement therapy. Pediatr Endocrinol Rev. 2014;12(Suppl 1):82\u20137.","journal-title":"Pediatr Endocrinol Rev"},{"key":"776_CR3","first-page":"1","volume-title":"The Online Metabolic and Molecular Bases of Inherited Disease","author":"GA Grabowski","year":"2010","unstructured":"Grabowski GA, Kolodny EH, Weinreb NJ, Rosenbloom BE, Prakash-Cheng A, Kaplan P, et al. Gaucher disease: phenotypic and genetic variation. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill Companies; 2010. p. 1\u201363."},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324:1464\u201370.","journal-title":"N Engl J Med"},{"key":"776_CR5","first-page":"472","volume":"11","author":"GM Pastores","year":"2010","unstructured":"Pastores GM. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010;11:472\u20138.","journal-title":"Curr Opin Investig Drugs"},{"key":"776_CR6","unstructured":"Cerezyme (imiglucerase for injection) [package insert]. Cambridge: Genzyme Corporation; 2011."},{"key":"776_CR7","unstructured":"VPRIV (velaglucerase alfa for injection) [package insert]. Lexington: Shire Human Genetic Therapies, Inc.; 2015."},{"key":"776_CR8","unstructured":"Elelyso (taliglucerase alfa) for injection [package insert]. New York: Pfizer Labs; 2016."},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","volume":"5","author":"Y Shaaltiel","year":"2007","unstructured":"Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007;5:579\u201390.","journal-title":"Plant Biotechnol J"},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1042\/BSR20130081","volume":"33","author":"Y Tekoah","year":"2013","unstructured":"Tekoah Y, Tzaban S, Kizhner T, Hainrichson M, Gantman A, Golembo M, et al. Glycosylation and functionality of recombinant glucocerebrosidase from various production systems. Biosci Rep. 2013;33:771\u201381.","journal-title":"Biosci Rep"},{"key":"776_CR11","first-page":"S49","volume":"111","author":"G Grabowski","year":"2014","unstructured":"Grabowski G, Golembo M, Shaaltiel Y. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology [abstract]. Mol Genet Metab. 2014;111:S49.","journal-title":"Mol Genet Metab"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","volume":"44","author":"CE Hollak","year":"2010","unstructured":"Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44:41\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"776_CR13","unstructured":"Refusal of the marketing authorisation for Elelyso (taliglucerase alfa) London, United Kingdom: European Medicine Agency; 2012 [November 22, 2012]. Available at: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002250\/WC500129076.pdf\n                    \n                  . Accessed June 20, 2017."},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nbt0612-472","volume":"30","author":"JL Fox","year":"2012","unstructured":"Fox JL. First plant-made biologic approved. Nat Biotechnol. 2012;30:472.","journal-title":"Nat Biotechnol"},{"key":"776_CR15","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Terreros Munoz E, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118:5767\u201373.","journal-title":"Blood"},{"key":"776_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"GM Pastores","year":"2014","unstructured":"Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, et al. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53:253\u201360.","journal-title":"Blood Cells Mol Dis"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bcmd.2014.10.002","volume":"54","author":"A Zimran","year":"2015","unstructured":"Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. Blood Cells Mol Dis. 2015;54:9\u201316.","journal-title":"Blood Cells Mol Dis"},{"key":"776_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/ajh.24369","volume":"91","author":"A Zimran","year":"2016","unstructured":"Zimran A, Duran G, Mehta A, Giraldo P, Rosenbaum H, Giona F, et al. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease. Am J Hematol. 2016;91:656\u201360.","journal-title":"Am J Hematol"},{"key":"776_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ajh.24399","volume":"91","author":"GM Pastores","year":"2016","unstructured":"Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, et al. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Am J Hematol. 2016;91:661\u20135.","journal-title":"Am J Hematol"},{"key":"776_CR20","doi-asserted-by":"crossref","unstructured":"Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, et al. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase. Blood Cells Mol Dis. 2018;68:163-72.","DOI":"10.1016\/j.bcmd.2016.10.005"},{"key":"776_CR21","doi-asserted-by":"crossref","unstructured":"Zimran A, Duran G, Giraldo P, Rosenbaum H, Giona F, Petakov M, et al. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naive patients with Gaucher disease. Blood Cells Mol Dis. 2016. [Epub ahead of print].","DOI":"10.1016\/j.bcmd.2016.07.002"},{"key":"776_CR22","doi-asserted-by":"publisher","first-page":"e0128986","DOI":"10.1371\/journal.pone.0128986","volume":"10","author":"R Abbas","year":"2015","unstructured":"Abbas R, Park G, Damle B, Chertkoff R, Alon S. Pharmacokinetics of novel plant cell-expressed taliglucerase alfa in adult and pediatric patients with Gaucher disease. PLoS One. 2015;10:e0128986.","journal-title":"PLoS One"},{"key":"776_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","volume":"71","author":"A Zimran","year":"1992","unstructured":"Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore). 1992;71:337\u201353.","journal-title":"Medicine (Baltimore)"},{"key":"776_CR24","first-page":"565","volume":"86","author":"S Zevin","year":"1993","unstructured":"Zevin S, Abrahamov A, Hadas-Halpern I, Kannai R, Levy-Lahad E, Horowitz M, et al. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med. 1993;86:565\u201373.","journal-title":"Q J Med"},{"key":"776_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpeds.2003.10.067","volume":"144","author":"J Charrow","year":"2004","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004;144:112\u201320.","journal-title":"J Pediatr"},{"key":"776_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","volume":"163","author":"GA Grabowski","year":"2004","unstructured":"Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr. 2004;163:58\u201366.","journal-title":"Eur J Pediatr"},{"key":"776_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160:603\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"776_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","volume":"46","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis. 2011;46:66\u201372.","journal-title":"Blood Cells Mol Dis"},{"key":"776_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","volume":"46","author":"L Bracoud","year":"2011","unstructured":"Bracoud L, Ahmad H, Brill-Almon E, Chertkoff R. Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model. Blood Cells Mol Dis. 2011;46:47\u201352.","journal-title":"Blood Cells Mol Dis"},{"key":"776_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","volume":"108","author":"M de Fost","year":"2006","unstructured":"de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006;108:830\u20135.","journal-title":"Blood"},{"key":"776_CR31","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835\u201343.","journal-title":"Arch Intern Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0776-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T19:24:02Z","timestamp":1550863442000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0776-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0776-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"assertion":[{"value":"29 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies reviewed herein were designed and conducted in compliance with the ethical principles of Good Clinical Practice guidelines in accordance with the Declaration of Helsinki. Investigators obtained informed written consent from each patient and\/or parent or guardian before study participation. The study protocols and the informed consent forms were reviewed and approved by the ethics committees\/institutional review boards for each study and at each study site.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ari Zimran was a consultant for Protalix BioTherapeutics during the course of the taliglucerase alfa studies and has received honoraria from Genzyme\/Sanofi, Pfizer, and Shire; his current institution, the Gaucher Clinic, receives grant\/research support from Genzyme\/Sanofi and Shire. Michael Wajnrajch and Betina Hernandez are employees of Pfizer Inc. Gregory M. Pastores received grant\/research support from Actelion, Alexion, Amicus\/GSK, BioMarin, Genzyme\/Sanofi, Protalix BioTherapeutics\/Pfizer, and Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"36"}}